Investigating the Benefits of Probiotics in Treating Irritable Bowel Syndrome

Abstract

Background: Irritable Bowel Syndrome (IBS) is a common gastrointestinal
disorder characterized by abdominal pain, bloating, and altered bowel habits.
Despite the availability of various treatments, management remains challenging
for many patients. Probiotics, live microorganisms that confer health benefits to
the host, have been investigated for their potential role in alleviating IBS
symptoms. This study aims to evaluate the effectiveness of probiotics in
reducing IBS symptoms compared to conventional treatments.
Methods: A randomized controlled trial was conducted with 250 participants
(aged 18–65 years) diagnosed with IBS. Participants were randomly assigned to
three groups: a probiotic group, a fiber supplementation group, and a
pharmacotherapy group. Symptom severity was assessed using the IBS Severity
Scoring System (IBS-SSS) and the Bristol Stool Scale (BSS) at baseline, 6
weeks, and 12 weeks.
Results: The probiotic group showed a 45% reduction in IBS-SSS scores,
compared to 30% in the fiber group and 28% in the pharmacotherapy group.
The probiotic group also exhibited improvements in stool consistency and
reduced bloating.
Conclusion: Probiotics demonstrated significant benefits in treating IBS, with
improvements comparable to traditional treatments. Probiotics should be
considered a viable option in the management of IBS symptoms, especially for
patients who prefer non-pharmacological treatments.